NASDAQ:OPK - Opko Health Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $2.10 +0.11 (+5.53 %) (As of 05/22/2019 07:31 AM ET)Previous Close$1.99Today's Range$2.00 - $2.1052-Week Range$1.92 - $6.40Volume3.05 million shsAverage Volume5.15 million shsMarket Capitalization$1.29 billionP/E RatioN/ADividend YieldN/ABeta1.81 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. The company's Pharmaceutical segment offers Rayaldee, a treatment for secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, a selective androgen receptor modulator for benign prostatic hyperplasia, and other urologic and metabolic conditions; and OPK88003, a once or twice weekly oxyntomodulin that is in Phase II trials for type 2 diabetes and obesity. It is also developing hGH-CTP, a once-weekly human growth hormone injection in Phase III clinical trial in partnership with Pfizer, Inc.; VARUBI for chemotherapy-induced nausea and vomiting; and Factor VIIa drug for hemophilia. In addition, this segment develops and produces specialty active pharmaceutical ingredients; and discovers drugs for the treatment of cancer, heart disease, metabolic disorders, and a range of genetic anomalies. Further, it develops, manufactures, markets, and sells pharmaceutical, nutraceutical, and veterinary products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro- intestinal products, hormones, and others. Additionally, the company operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. OPKO Health, Inc. was incorporated in 1991 and is headquartered in Miami, Florida. Receive OPK News and Ratings via Email Sign-up to receive the latest news and ratings for OPK and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:OPK Previous Symbol CUSIP68375N10 CIK944809 Webhttp://www.opko.com/ Phone305-575-4100Debt Debt-to-Equity Ratio0.13 Current Ratio1.10 Quick Ratio0.99Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$990.30 million Price / Sales1.31 Cash FlowN/A Price / Cash FlowN/A Book Value$2.86 per share Price / Book0.73Profitability EPS (Most Recent Fiscal Year)($0.25) Net Income$-153,040,000.00 Net Margins-19.92% Return on Equity-9.86% Return on Assets-7.03%Miscellaneous Employees5,690 Outstanding Shares615,601,000Market Cap$1.29 billion Next Earnings Date8/6/2019 (Estimated) OptionableOptionable Opko Health (NASDAQ:OPK) Frequently Asked Questions What is Opko Health's stock symbol? Opko Health trades on the NASDAQ under the ticker symbol "OPK." How were Opko Health's earnings last quarter? Opko Health Inc. (NASDAQ:OPK) announced its earnings results on Tuesday, May, 7th. The biotechnology company reported ($0.14) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.06) by $0.08. The biotechnology company earned $222.50 million during the quarter, compared to analyst estimates of $241.27 million. Opko Health had a negative return on equity of 9.86% and a negative net margin of 19.92%. Opko Health's revenue for the quarter was down 12.7% on a year-over-year basis. During the same period in the previous year, the company posted ($0.08) earnings per share. View Opko Health's Earnings History. When is Opko Health's next earnings date? Opko Health is scheduled to release their next quarterly earnings announcement on Tuesday, August 6th 2019. View Earnings Estimates for Opko Health. What price target have analysts set for OPK? 2 Wall Street analysts have issued 1 year price objectives for Opko Health's stock. Their forecasts range from $5.00 to $20.00. On average, they expect Opko Health's share price to reach $12.50 in the next twelve months. This suggests a possible upside of 495.2% from the stock's current price. View Analyst Price Targets for Opko Health. What is the consensus analysts' recommendation for Opko Health? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Opko Health in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Opko Health. What are Wall Street analysts saying about Opko Health stock? Here are some recent quotes from research analysts about Opko Health stock: 1. According to Zacks Investment Research, "OPKO Health has gained significantly from RAYALDEE contribution in recent times. Also, OPKO Health’s utilization of the 4Kscore remains strong, with nearly 20,000 tests registered in recent times. OPKO Health announced that the FDA has approved the company’s point-of-care Sangia Total PSA Test using the Claros 1 Analyzer. Several metabolic and endocrinology programs that are underway should provide OPKO Health a competitive advantage. On the flip side, OPKO Health’s operating margins look pressed at the moment. Also, the company faces cutthroat competition in the MedTech space. Moreover, the decline in R&D expenses indicates reduced focus on innovation. Sluggishness in the Product revenue segment is an added headwind. The stock underperformed its industry in the last six months." (4/30/2019) 2. Barrington Research analysts commented, "We are maintaining our OUTPERFORM investment rating on OPK shares but are reducing our 12-month price target to $5 from $7. Even given the reduced target, price appreciation potential remains at approximately 80%, hence our constructive rating. We arrive at our price target via a DCF methodology for its current commercial business plus the hGH-CTP program. We assign an additional $1 of value for the remainder of OPKO’s product pipeline." (2/28/2019) 3. Cantor Fitzgerald analysts commented, ". We reiterate our OW rating and 12-month price target of $20 for OPK shares post a 2Q18 EPS beat. We continue to think that the long-term sales and earnings potential of OPK’s business is underappreciated and that upward earnings revisions in 2019+ to levels not reflected in consensus expectations should drive the stock higher. We expect upward earnings revisions to come from the uptake of Rayaldee, commercialization of OPK’s branded drug pipeline, and BioReference sales growth and margin expansion." (8/7/2018) Has Opko Health been receiving favorable news coverage? Press coverage about OPK stock has trended somewhat positive this week, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Opko Health earned a daily sentiment score of 1.5 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the next few days. Are investors shorting Opko Health? Opko Health saw a increase in short interest in April. As of April 30th, there was short interest totalling 87,047,375 shares, an increase of 0.6% from the April 15th total of 86,542,383 shares. Based on an average daily volume of 4,412,254 shares, the days-to-cover ratio is currently 19.7 days. Currently, 24.2% of the shares of the company are sold short. View Opko Health's Current Options Chain. Who are some of Opko Health's key competitors? Some companies that are related to Opko Health include Ascendis Pharma A/S (ASND), Array Biopharma (ARRY), Horizon Therapeutics (HZNP), TESARO (TSRO), United Therapeutics (UTHR), Taro Pharmaceutical Industries (TARO), Alkermes (ALKS), American Brivision (Holding) (ABVC), Evotec (EVTCY), Blueprint Medicines (BPMC), HUTCHISON CHINA/S (HCM), Ultragenyx Pharmaceutical (RARE), ACADIA Pharmaceuticals (ACAD), Global Blood Therapeutics (GBT) and FibroGen (FGEN). What other stocks do shareholders of Opko Health own? Based on aggregate information from My MarketBeat watchlists, some companies that other Opko Health investors own include TherapeuticsMD (TXMD), bluebird bio (BLUE), Micron Technology (MU), Gray Television (GTN), Allergan (AGN), Gilead Sciences (GILD), Bausch Health Companies (BHC), Novavax (NVAX), AT&T (T) and Celldex Therapeutics (CLDX). Who are Opko Health's key executives? Opko Health's management team includes the folowing people: Dr. Phillip Frost, Chairman & CEO (Age 83)Dr. Jane H. Hsiao M.B.A., Ph.D., MBA, Vice Chairman & CTO (Age 72)Mr. Adam E. Logal, Sr. VP, CFO, Chief Accounting Officer & Treasurer (Age 41)Mr. Steven D. Rubin, Exec. VP of Admin. & Director (Age 59)Ms. Kate Inman, Gen. Counsel & Sec. (Age 46) Who are Opko Health's major shareholders? Opko Health's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (4.90%), Geode Capital Management LLC (0.74%), Dimensional Fund Advisors LP (0.70%), Northern Trust Corp (0.65%), Morgan Stanley (0.55%) and Charles Schwab Investment Management Inc. (0.37%). Company insiders that own Opko Health stock include Adam Logal, Jane Ph D Hsiao, John A Paganelli, Opko Health, Inc, Phillip Md Et Al Frost, Richard A Lerner, Richard C Pfenniger Jr, Robert Scott Fishel and Steven D Rubin. View Institutional Ownership Trends for Opko Health. Which institutional investors are selling Opko Health stock? OPK stock was sold by a variety of institutional investors in the last quarter, including First Manhattan Co., Teton Advisors Inc., Ladenburg Thalmann Financial Services Inc., Jane Street Group LLC, Northern Trust Corp, Connor Clark & Lunn Investment Management Ltd., BlackRock Inc. and Raymond James & Associates. View Insider Buying and Selling for Opko Health. Which institutional investors are buying Opko Health stock? OPK stock was purchased by a variety of institutional investors in the last quarter, including Morgan Stanley, Marshall Wace LLP, Wells Fargo & Company MN, Geode Capital Management LLC, ClariVest Asset Management LLC, Nordea Investment Management AB, JPMorgan Chase & Co. and Pictet Asset Management Ltd.. Company insiders that have bought Opko Health stock in the last two years include Adam Logal, Jane Ph D Hsiao, John A Paganelli, Opko Health, Inc, Phillip Md Et Al Frost, Richard A Lerner, Richard C Pfenniger Jr, Robert Scott Fishel and Steven D Rubin. View Insider Buying and Selling for Opko Health. How do I buy shares of Opko Health? Shares of OPK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Opko Health's stock price today? One share of OPK stock can currently be purchased for approximately $2.10. How big of a company is Opko Health? Opko Health has a market capitalization of $1.29 billion and generates $990.30 million in revenue each year. The biotechnology company earns $-153,040,000.00 in net income (profit) each year or ($0.25) on an earnings per share basis. Opko Health employs 5,690 workers across the globe. What is Opko Health's official website? The official website for Opko Health is http://www.opko.com/. How can I contact Opko Health? Opko Health's mailing address is 4400 BISCAYNE BLVD., MIAMI FL, 33137. The biotechnology company can be reached via phone at 305-575-4100 or via email at [email protected] MarketBeat Community Rating for Opko Health (NASDAQ OPK)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 399 (Vote Outperform)Underperform Votes: 367 (Vote Underperform)Total Votes: 766MarketBeat's community ratings are surveys of what our community members think about Opko Health and other stocks. Vote "Outperform" if you believe OPK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPK will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/22/2019 by MarketBeat.com StaffFeatured Article: Leveraged Buyout (LBO) Explained Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.